Transition Therapeutics Announces Fiscal 2007 Year End Financi... (e products patents and technologies acqu...)

Transition Therapeutics Announces Fiscal 2007 Year End Financial Results

Date:9/12/2007

e products, patents and technologies acquired from ENI as well as the amortization of the NeuroMedix technology acquired May 9, 2007.

Interest income, net for the fiscal year ended June 30, 2007, was $1,226,099 as compared to $350,380 for the fiscal year ended June 30, 2006. The increase in interest income, net of $875,719 primarily resulted from increased cash balances due to the November 2006 private placement and the upfront payment received from Elan.

Recovery of future income taxes for the year ended June 30, 2007 increased by $1,631,901 or 149% to a recovery of $2,729,422 as compared to a recovery of $1,097,521 for the year ended June 30, 2006. The majority of the increase in recovery of future income taxes for fiscal 2007 is due to the recognition of future income tax assets resulting from the amalgamation of Ellipsis Neurotherapeutics Inc., 1255205 Ontario Inc., 1255206 Ontario Inc. and Waratah Pharmaceuticals Inc. As a result of the amalgamation, the Company has adjusted the valuation allowance on future income tax assets and has recognized a future income tax asset to the extent of offsetting future income tax liabilities of the amalgamated entity. Additional future income tax recovery also arose from changes in temporary differences.

About Transition

----------------

Transition is a biopharmaceutical company, developing novel therapeutics for disease indications with large markets. Transition's lead products include ELND-005/AZD-103 for the treatment of Alzheimer's disease and regenerative therapies E1-I.N.T.(TM) and GLP1-I.N.T.(TM) for the treatment of diabetes. Transition has an emerging pipeline of preclinical drug candidates developed using its proprietary drug discovery engine. Transition's shares are listed on the NASDAQ under the symbol "TTHI" and the Toronto Stock Exchange under the symbol "TTH". For additional information about the company, please visit ht
'/>"/>

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19
Related medicine news :

1. Mans Transition from Foragers to Agriculturalist Led to Increase in Birth Rates
2. Rocky Transition to the Medicare Drug Program
3. Customized Post Operation Care Offers Patients a Smooth Transition to Patients into the Community
4. Mental Health - NHS Trust Commences Specialist Transition Service
5. Permanent Weight Loss Requires Transition to Healthy Eating
6. VBI Provides Potential Targets to Diabetes Therapeutics
7. CELL THERAPEUTICS PAYS Heavily to Resolve Dispute FOR ALLEGED ILLEGAL MARKETING OF CANCER DRUG
8. PM announces a new health care order for India
9. Ramdoss Announces Introduction of RCH-II
10. Britain Announces Third Transfusion Related Mad Cow Case
11. Gates Foundation Announces $287 Million In Grants Towards AIDS Vaccine

Post Your Comments:

Transition Therapeutics Announces Fiscal 2007 Year End Financi...(e products patents and technologies acqu...),Health